Siga Technologies Inc. (SIGA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Siga Technologies Q1 Earnings Call Highlights
Siga Technologies NASDAQ: SIGA reported a first-quarter loss as product deliveries remained minimal, but management said it expects a pickup in the second quarter tied to an international order and additional deliveries to the U.S. Strategic National Stockpile.
SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript
SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript
SIGA Technologies, Inc. (SIGA) Q4 2025 Earnings Call Transcript
SIGA Technologies, Inc. (SIGA) Q4 2025 Earnings Call Transcript
Siga Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 37,728 | $201,845 | $162,607.68 | -$39,237.32 | -19.44% |
| JC Joseph Castro Nuveen LLC | 100,899 | $552,822.33 | $434,874.69 | -$117,947.64 | -21.34% |
| KC Kimberly Cappellano Private Wealth Asset Management LLC | 1,700 | $9,536.5 | $7,327 | -$2,209.5 | -23.17% |
| BA Bobby Adusumilli SJS Investment Consulting Inc. | 66 | $603.9 | $284.46 | -$319.44 | -52.9% |
| LP Li Peng China Universal Asset Management Co. Ltd. | 11,669 | $86,507.13 | $50,410.08 | -$36,097.05 | -41.73% |
Siga Technologies Inc. (SIGA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Siga Technologies Inc. ever had a stock split?
Siga Technologies Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Diem Nguyen CEO | NASDAQ (NMS) Exchange | 826917106 CUSIP |
| US Country | 46 Employees | 7 Apr 2026 Last Dividend | - Last Split | 9 Sep 1997 IPO Date |
Overview
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company with a specific focus on health security markets within the United States. Incorporated in 1995, the company has established its headquarters in New York, New York. SIGA Technologies is dedicated to the development, manufacture, and commercialization of solutions for serious conditions and diseases that affect health security. The core mission of SIGA revolves around enhancing preparedness and response capabilities against biological threats, thereby contributing significantly to public health defense mechanisms.
Products and Services
TPOXX (tecovirimat)
SIGA Technologies' flagship product is TPOXX, an antiviral medication that is taken orally. TPOXX has been specifically developed for the treatment of human smallpox disease caused by the variola virus. This drug represents a significant advancement in the field of biodefense, offering a critical tool in the event of a smallpox outbreak. Its approval and availability highlight SIGA’s pivotal role in enhancing national and global preparedness against potential bioterrorism or naturally occurring outbreaks of this deadly virus.
